Page last updated: 2024-12-11
variecolin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
variecolin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6480205 |
| CHEMBL ID | 519317 |
| CHEBI ID | 66349 |
| MeSH ID | M0397252 |
Synonyms (15)
| Synonym |
|---|
| isopropenyl-trimethyl-oxo-[?]carbaldehyde |
| variecolin |
| cyclopenta[4,5]cyclooct[1,2-e]indene-8-carboxaldehyde, 1,2,2a,3,4,5,5a,5b,6,8a,9,10,11,11a,12,12a-hexadecahydro-2a,11,12a-trimethyl-5-(1-methylethenyl)-9-oxo-, (2as,5s,5as,5bs,8ar,11s,11as,12ar)- |
| bdbm50260106 |
| CHEMBL519317 , |
| chebi:66349 , |
| 133101-16-3 |
| Q15427952 |
| (1r,3s,4s,7r,8e,11s,12s,13s,16s)-1,4,16-trimethyl-6-oxo-13-prop-1-en-2-yltetracyclo[9.7.0.03,7.012,16]octadec-8-ene-8-carbaldehyde |
| (2as,5s,5as,5bs,8ar,11s,11as,12ar)-1,2,2a,3,4,5,5a,5b,6,8a,9,10,11,11a,12,12a-hexadecahydro-2a,11,12a-trimethyl-5-(1-methylethenyl)-9-oxocyclopenta(4,5)cyclooct(1,2-e)indene-8-carboxaldehyde |
| ryl8qsn52u , |
| (-)-variecolin |
| cyclopenta(4,5)cyclooct(1,2-e)indene-6-carboxaldehyde, 1,2,3,3a,3b,4,6a,7,8,9,9a,10,10a,11,12,12a-hexadecahydro-9,10a,12a-trimethyl-3-(1-methylethenyl)-7-oxo-, (3s,3as,3bs,6ar,9s,9as,10ar,12as)- |
| cyclopenta(4,5)cyclooct(1,2-e)indene-8-carboxaldehyde, 1,2,2a,3,4,5,5a,5b,6,8a,9,10,11,11a,12,12a-hexadecahydro-2a,11,12a-trimethyl-5-(1-methylethenyl)-9-oxo-, (2as,5s,5as,5bs,8ar,11s,11as,12ar)- |
| DTXSID701045557 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| Aspergillus metabolite | Any fungal metabolite produced during a metabolic reaction in the mould, Aspergillus. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (2)
| Class | Description |
|---|---|
| sesterterpenoid | Any terpenoid derived from a sesterterpene. The term includes compounds in which the C25 skeleton of the parent sesterterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). Sometimes sesterterpenoids are erroneously referred to as sesterpenoids. |
| enal | An alpha,beta-unsaturated aldehyde of general formula R(1)R(2)C=CR(3)-CH=O in which the aldehydic C=O function is conjugated to a C=C double bond at the alpha,beta position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| C-C chemokine receptor type 5 | Homo sapiens (human) | IC50 (µMol) | 9.0000 | 0.0002 | 0.2567 | 9.0000 | AID333378 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (20)
Molecular Functions (10)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| virus receptor activity | C-C chemokine receptor type 5 | Homo sapiens (human) |
| actin binding | C-C chemokine receptor type 5 | Homo sapiens (human) |
| phosphatidylinositol phospholipase C activity | C-C chemokine receptor type 5 | Homo sapiens (human) |
| chemokine receptor activity | C-C chemokine receptor type 5 | Homo sapiens (human) |
| protein binding | C-C chemokine receptor type 5 | Homo sapiens (human) |
| coreceptor activity | C-C chemokine receptor type 5 | Homo sapiens (human) |
| C-C chemokine receptor activity | C-C chemokine receptor type 5 | Homo sapiens (human) |
| C-C chemokine binding | C-C chemokine receptor type 5 | Homo sapiens (human) |
| identical protein binding | C-C chemokine receptor type 5 | Homo sapiens (human) |
| chemokine (C-C motif) ligand 5 binding | C-C chemokine receptor type 5 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (5)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cell surface | C-C chemokine receptor type 5 | Homo sapiens (human) |
| endosome | C-C chemokine receptor type 5 | Homo sapiens (human) |
| plasma membrane | C-C chemokine receptor type 5 | Homo sapiens (human) |
| external side of plasma membrane | C-C chemokine receptor type 5 | Homo sapiens (human) |
| cell surface | C-C chemokine receptor type 5 | Homo sapiens (human) |
| external side of plasma membrane | C-C chemokine receptor type 5 | Homo sapiens (human) |
| cytoplasm | C-C chemokine receptor type 5 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID333378 | Displacement of human [125I]MIP-1-alpha from human CCR5 overexpressed in CHO cells by SPA | 2004 | Journal of natural products, Oct, Volume: 67, Issue:10 | Inhibition of the human chemokine receptor CCR5 by variecolin and variecolol and isolation of four new variecolin analogues, emericolins A-D, from Emericella aurantiobrunnea. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 18.02
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.02) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||